Skip to product information
1 of 1

Rat Anti-Human IL-13 Antibody (S-4442)

Rat Anti-Human IL-13 Antibody (S-4442)

Catalog Number: S0B80102 Application: ICFCM Reactivity: Hu Conjugation: Unconjugated Brand: Starter
Price:
Regular price $100 USD
Regular price Sale price $100 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rat
Antigen IL-13
Synonyms Interleukin-13; NC30; IL13
Location Secreted
Accession P35225
Clone Number S-4442
Antibody Type Rat mAb
Isotype IgG1
Application ICFCM
Reactivity Hu
Purification Protein G
Concentration 2 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
ICFCM 1:200 Hu

Background

Interleukin-13 (IL-13) is a pleiotropic cytokine primarily secreted by activated type 2 helper T cells (Th2), group 2 innate lymphoid cells (ILC2s), mast cells, and basophils, playing a central role in regulating inflammatory and immune responses, particularly those associated with allergic reactions and parasitic infections. Structurally homologous to IL-4, IL-13 exerts its biological effects by binding to a heterodimeric receptor complex composed of the IL-4Rα chain and the specific IL-13Rα1 chain, which subsequently activates the JAK-STAT signaling pathway, notably STAT6, to modulate gene expression in target cells such as epithelial cells, fibroblasts, and B cells. Its key physiological functions include inducing class switching to IgE in B cells, stimulating mucus hypersecretion and goblet cell metaplasia in airway epithelium, promoting alternative activation (M2 polarization) of macrophages, and driving tissue fibrosis by enhancing collagen production, making it a critical mediator in the pathogenesis of asthma, atopic dermatitis, and other fibrotic disorders, thereby establishing it as a major therapeutic target for biologics like dupilumab and tralokinumab that aim to block the IL-4/IL-13 signaling axis.